Clinical trials: Semaglutide, completed
Diabetes Mellitus, Type 2
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D).
- Trial name
- NCT06403761
- Testing
- Semaglutide, Cagrilintide
- Where
- Germany
- Volunteers
- 158 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg…
- Trial name
- NCT04817644
- Testing
- Oral semaglutide
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Gastroparesis
Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1-RA) such as semaglutide (Ozempic™, Rybelsus™, Wegovy™) were first introduced as a therapeutic agent for type 2 diabetes mellitus but they are being increasingly used to…
- Trial name
- GUST (NCT06292065)
- Testing
- Point-of-care gastric ultrasound
- Where
- Belgium
- Volunteers
- 88 people
- Sponsor
- Nils Vlaeminck
Type 2 Diabetes, Overweight
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
- Trial name
- TIRZSEMA-CVOT (NCT07096063)
- Testing
- Tirzepatide, Dulaglutide, Semaglutide
- Where
- United States
- Volunteers
- 887,132 people
- Sponsor
- Brigham and Women's Hospital
Diabetes, Healthy
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the influence of oral semaglutide on pharmacokinetics (the exposure of the trial drug in the body) of metformin and digoxin in healthy subjects.
- Trial name
- NCT02249910
- Testing
- semaglutide, metformin, digoxin
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
A single arm no randomized clinical trial evaluated the effectiveness and safety of once weekly semaglutide in adults with type 2 diabetes militus and obesity whose glycemic control remained inadequate despite standard therapy.
- Trial name
- NCT07732218
- Testing
- Semaglutide (Ozempic®)
- Where
- Pakistan
- Volunteers
- 95 people
- Sponsor
- Rehman Medical Institute - RMI
Obesity
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in…
- Trial name
- STEP UP (NCT05646706)
- Testing
- Semaglutide
- Where
- 107 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,407 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this…
- Trial name
- NCT06289504
- Testing
- Cagrilintide, Semaglutide, Atorvastatin
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D).
- Trial name
- NCT05478252
- Testing
- Semaglutide J, Semaglutide B
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Gastric Retention
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying.
- Trial name
- RESIDUAL (NCT06500143)
- Testing
- Gastric ultrasound
- Where
- Canada
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE ITALY (NCT04094415)
- Testing
- Semaglutide
- Where
- 39 sites in Italy
- Volunteers
- 581 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2…
- Trial name
- SUSTAIN™ 3 (NCT01885208)
- Testing
- semaglutide, exenatide
- Where
- 146 sites in United States, Argentina and 11 more
- Volunteers
- 813 people
- Sponsor
- Novo Nordisk A/S